Generic Name: cenicriviroc
Drug Class: NAFLD/NASH Medications
Approval Status: Experimental
Generic Version Available: No
Experimental Code: TAK-652, TBR-652
Cenicriviroc is a C-C chemokine receptor type 2 and type 5 antagonist in Phase 3 clinical trials for treatment of non-alcoholic steatohepatitis (NASH). Cenicriviroc was aquired by Allergan from Tobira Therapeutics.
Dosing Info: N/A
Last Reviewed: February 4, 2019